Track all markets on TradingView Eli Lilly’s (NYSE:LLY) impressive market performance has raised eyebrows, propelled by its recently approved weight loss drug, Zepbound. The drugmaker unseated Tesla (NASDAQ: TSLA) from the “Magnificent 7” list of top-performing stocks in late January. Despite a slight dip, Lilly’s market capitalization remains formidable, hovering around $680 billion as of … Eli Lilly’s Obesity Drug Success: Can the Surge Last?
The post Eli Lilly’s Obesity Drug Success: Can the Surge Last? appeared first on ImaStockTrader.